{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nepafenac+0.1%25",
    "query": {
      "intervention": "Nepafenac 0.1%"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nepafenac+0.1%25&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T12:00:14.776Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00377546",
      "title": "Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Vitrectomy"
      ],
      "interventions": [
        {
          "name": "Nepafenac",
          "type": "DRUG"
        },
        {
          "name": "Ketorolac LS, Bromfenac",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Innovative Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-09-25",
      "last_synced_at": "2026-09-27T12:00:14.776Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00377546"
    },
    {
      "nct_id": "NCT00828477",
      "title": "Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Intraocular Pressure"
      ],
      "interventions": [
        {
          "name": "Xibrom",
          "type": "DRUG"
        },
        {
          "name": "Nevanac",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bp Consulting, Inc",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2009-01",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2009-06-10",
      "last_synced_at": "2026-09-27T12:00:14.776Z",
      "location_count": 1,
      "location_summary": "3340 6 Mile Rd Livonia, Michigan",
      "locations": [
        {
          "city": "3340 6 Mile Rd Livonia",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00828477"
    },
    {
      "nct_id": "NCT01318499",
      "title": "Nepafenac 0.3% Two Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Nepafenac Ophthalmic Suspension, 0.3%",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac Ophthalmic Suspension, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac Vehicle 0.3%",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1342,
      "start_date": "2011-03",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2012-12-17",
      "last_synced_at": "2026-09-27T12:00:14.776Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01318499"
    },
    {
      "nct_id": "NCT00333255",
      "title": "Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Nepafenac Ophthalmic Suspension, 0.1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 267,
      "start_date": "2005-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-07-08",
      "last_synced_at": "2026-09-27T12:00:14.776Z",
      "location_count": 1,
      "location_summary": "Nacogdoches, Texas",
      "locations": [
        {
          "city": "Nacogdoches",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00333255"
    },
    {
      "nct_id": "NCT01331005",
      "title": "NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "nepafenac 0.1% drops",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2011-05",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2025-03-10",
      "last_synced_at": "2026-09-27T12:00:14.776Z",
      "location_count": 32,
      "location_summary": "Loma Linda, California • Palm Springs, California • Santa Barbara, California + 29 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Westlake Village",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01331005"
    },
    {
      "nct_id": "NCT01109173",
      "title": "Confirmatory Study Nepafenac 0.3%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Nepafenac Ophthalmic Suspension, 0.3%",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac Ophthalmic Suspension, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac Ophthalmic Suspension 0.3% Vehicle",
          "type": "OTHER"
        },
        {
          "name": "NEVANAC Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2120,
      "start_date": "2010-06",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2012-11-30",
      "last_synced_at": "2026-09-27T12:00:14.776Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01109173"
    },
    {
      "nct_id": "NCT00818844",
      "title": "Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Epiretinal Membrane"
      ],
      "interventions": [
        {
          "name": "Nepafenac 0.1%",
          "type": "DRUG"
        },
        {
          "name": "BSS",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2009-01",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2015-08-14",
      "last_synced_at": "2026-09-27T12:00:14.776Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00818844"
    },
    {
      "nct_id": "NCT01001806",
      "title": "A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cataracts"
      ],
      "interventions": [
        {
          "name": "Ketorolac Tromethamine 0.45%",
          "type": "DRUG"
        },
        {
          "name": "bromfenac 0.09%",
          "type": "DRUG"
        },
        {
          "name": "nepafenac 0.1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Frank A. Bucci, Jr., M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2009-10",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2011-10-03",
      "last_synced_at": "2026-09-27T12:00:14.776Z",
      "location_count": 1,
      "location_summary": "Wilkes-Barre, Pennsylvania",
      "locations": [
        {
          "city": "Wilkes-Barre",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01001806"
    },
    {
      "nct_id": "NCT00330798",
      "title": "A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Photorefractive Keratectomy"
      ],
      "interventions": [
        {
          "name": "nepafenac 0.1%",
          "type": "DRUG"
        },
        {
          "name": "ketorolac 0.4%",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2006-02",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2016-11-18",
      "last_synced_at": "2026-09-27T12:00:14.776Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00330798"
    },
    {
      "nct_id": "NCT00939276",
      "title": "Macular Edema Incidence/Severity Reduction With Nevanac",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac ophthalmic suspension vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2009-08",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2012-10-23",
      "last_synced_at": "2026-09-27T12:00:14.776Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00939276"
    }
  ]
}